Analysts expect Neurocrine Biosciences Inc to report revenue of 1.02 B for Q4 26, against a range of 924.65 M to 1.11 B. The most recent reported quarter, Q3 26, came in at 1.12 B, a 10.3% beat against the 1.01 B consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 627.70 M | 572.60 M | 687.50 M | 794.90 M | 805.50 M | 814.50 M | 959.00 M | 1.12 B | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 639.88 M | 569.68 M | 705.20 M | 854.65 M | 833.82 M | 782.76 M | 1.02 B | 1.07 B | 1.11 B | 1.13 B | 1.20 B | 1.17 B | 1.46 B | 1.15 B | 1.29 B | 1.44 B | |||||||||
| Low Estimate | 582.36 M | 526.93 M | 659.11 M | 724.13 M | 702.27 M | 712.54 M | 838.51 M | 961.19 M | 924.65 M | 966.17 M | 1.03 B | 1.10 B | 1.23 B | 984.49 M | 1.06 B | 1.32 B | |||||||||
| Consensus Estimate | 611.12 M | 548.31 M | 682.15 M | 789.39 M | 768.05 M | 747.65 M | 928.22 M | 1.01 B | 1.02 B | 1.05 B | 1.12 B | 1.13 B | 1.35 B | 1.07 B | 1.17 B | 1.38 B |
Analysts expect Neurocrine Biosciences Inc to report earnings per share of 1.96 for Q4 26, against a range of 1.81 to 2.11. The most recent reported quarter, Q3 26, came in at 1.96, a 3.9% miss against the 2.04 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 1.00 | 0.08 | 1.06 | 2.04 | 1.48 | 1.91 | 1.39 | 1.96 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 1.65 | 0.60 | 1.06 | 1.65 | 1.84 | 1.39 | 1.89 | 2.16 | 2.11 | 2.23 | 2.70 | 2.57 | 2.73 | 2.43 | 4.44 | 3.31 | |||||||||
| Low Estimate | 1.37 | 0.52 | 0.96 | 1.39 | 1.60 | 1.17 | 1.55 | 1.92 | 1.81 | 1.85 | 2.28 | 2.21 | 2.37 | 2.09 | 4.12 | 2.93 | |||||||||
| Consensus Estimate | 1.51 | 0.56 | 1.01 | 1.52 | 1.72 | 1.28 | 1.72 | 2.04 | 1.96 | 2.04 | 2.49 | 2.39 | 2.55 | 2.26 | 4.28 | 3.12 |
Pull Wall Street consensus for Neurocrine Biosciences Inc (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=NBIX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "NBIX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=NBIX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();